News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
Events Partner Content 4th Clinical Regulatory Medical Writing Forum The premier medical writing event dedicated to addressi
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News Pfizer chief suggests no BMS bid - for now Ian Read won't quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb - but says it won't make any major acquisitions
News Takeda gets return on Ariad buy with approval of brigatinib But Japanese pharma bracing for US patent expiry on blockbuster Velcade
News Australia starts probe into AI infiltration of Medicare The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
